The first 3D map of SARS-CoV-2,, has been produced by a collaboration of coronavirus researchers at the University of Texas at Austin and the National Institutes of Health. Heralded as a breakthrough, the map provides a stepping stone to the development of antivirals or vaccines to stymie the virus.
In under two months, infections of the novel coronavirus have soared past 75,000 andin China and abroad. The World Health Organization has declared the outbreak a public health emergency of international concern and when it , it added that a vaccine was likely 18 months away.
But scientists are mobilizing their resources quickly,, and turning experiments into peer-reviewed research in a matter of weeks.
That’s the case for Jason McLellan, a structural biochemist, and his team at UT Austin who have been studying similar coronaviruses for years. Their latest study, published in the journal Science on Wednesday, took advantage of state-of-the-art technology at the university to map the molecular structure of SARS-CoV-2, with a particular focus on the virus’ “spike protein.” The protein is critical to the viruses survival because it enables it to get inside human cells and begin making copies of itself. But what makes it dangerous also makes it a target.
The chief function of a vaccine is to prime the immune system. They work by presenting small parts of harmful pathogens like viruses and bacteria to our army of immune cells. It’s like a molecular “WANTED!” poster — the immune system gets a good look at any nasty bugs and starts to keep watch. If the real virus or bacteria sneak into the body, the immune system is ready and sends out an army of cells and antibodies to stop the invader.
After Chinese researchers shared the genetic sequence of the virus in January, the team were able to design and produce samples of the spike protein in the lab. Using a specialized form of microscopy, they then mapped its structure.
The research team showed there are similarities in the way the spike proteins work between the coronavirus responsible for the 2002-2003 SARS outbreak and the novel virus, SARS-CoV-2. However, the latter appears to bind to human cells much more strongly than the SARS virus did and antibodies against the first SARS virus don’t seem to react to the new virus in the same way.
Nevertheless, creating the 3D atomic scale map of the spike protein in SARS-CoV-2, the team were able to show it can elicit an immune response, making it a viable molecule to speed up vaccine design and development.